News
In 2022, Novartis said it would cut 8,000 jobs globally, Reuters reported, which would save the company $1 billion over the next two years Global drugmaker Novartis will lay off 427 employees who ...
Vanrafia, 2nd drug in Novartis' IgAN troika, crosses FDA finish line in payday for Chinook investors
When Novartis bought kidney disease biotech Chinook Therapeutics in 2023 for $3.2 billion upfront, the deal included a conditional payment tied to the timely FDA approval of atrasentan without a ...
Entresto, approved in heart failure since 2015, has long been one of Novartis’ top growth drivers, bringing home $4.05 billion in U.S. sales in 2024. That said, a key combination patent on the ...
Another wave of layoffs will impact Novartis‘ U.S. headquarters in New Jersey. In a filing with the state Department of Labor & Workforce Development, the East Hanover-based Swiss pharmaceutical ...
NORTHAMPTON, MA / ACCESS Newswire / April 4, 2025 / Elanco: Recently, Elanco marked a significant milestone at its Huningue, France site by breaking ground on a 5,000 sq/m site expansion project.
Novartis signed on to become the National Football League’s first-ever corporate pharmaceutical partner. As part of the new multi-year deal, the Swiss pharma giant said it aims to empower ...
Spécialisé dans la santé animale, Elanco investit 35 millions d’euros pour l’extension de son site de production basé à Huningue dans le Haut-Rhin. Ce projet, qui doit voir le jour ...
TOKYO, March 17 (Reuters) - Swiss pharmaceutical giant Novartis (NOVN.S), opens new tab will watch "very carefully" how the reciprocal tariff policy proposed by the United States unfolds in early ...
ZURICH, March 19 (Reuters) - Swiss drugmaker Novartis (NOVN.S), opens new tab is ending its use of diverse panels for all of its hiring in the United States, the company told Reuters on Wednesday ...
North Carolina economic development officials have terminated an economic incentives agreement for Novartis Gene Therapies, which hasn’t met hiring targets tied to a package that promised up to ...
Nearly six years ago, the Food and Drug Administration approved Zolgensma, a Novartis gene therapy for the fatal neuron-wasting disease spinal muscular atrophy. It heralded a new era of genetic ...
Relégué l’an passé, Huningue vit une nouvelle saison extrêmement difficile. Les Frontaliers veulent corriger le tir pour éviter une deuxième chute consécutive. L’entraineur-joueur Brice ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results